- Home
- CCEC vs GHRS Comparison
CCEC vs GHRS Comparison
Compare CCEC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEC | GHRS |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Greece | Ireland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CCEC | GHRS |
|---|---|---|
| Price | $20.78 | $15.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $25.50 | ★ $32.90 |
| AVG Volume (30 Days) | 4.9K | ★ 248.6K |
| Earning Date | 02-06-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 304.00 | N/A |
| EPS | ★ 4.79 | N/A |
| Revenue | ★ $421,795,000.00 | N/A |
| Revenue This Year | $14.29 | N/A |
| Revenue Next Year | $12.32 | N/A |
| P/E Ratio | $4.28 | ★ N/A |
| Revenue Growth | ★ 32.74 | N/A |
| 52 Week Low | $14.09 | $7.98 |
| 52 Week High | $24.83 | $19.51 |
Technical Indicators
Market Signals| Indicator | CCEC | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 47.80 |
| Support Level | $20.21 | $13.60 |
| Resistance Level | $22.58 | $15.88 |
| Average True Range (ATR) | 0.52 | 0.94 |
| MACD | -0.13 | -0.20 |
| Stochastic Oscillator | 23.84 | 42.46 |
Price Performance
Historical ComparisonAbout CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.